Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
For detailed injection-specific protocols , the numbers above serve as your baseline reference
How it works: JAK2/growth hormone receptor upregulation: BPC-157 increases growth hormone receptor expression in tendon fibroblasts, sensitizing tissue to healing signals and accelerating structural repair FAK-paxillin pathway activation: enhances fibroblast migration and collagen deposition through focal adhesion kinase signaling, directly supporting connective tissue regeneration eNOS-driven angiogenesis: upregulates endothelial nitric oxide synthase to promote new blood vessel formation, improving oxygen and nutrient delivery to hypovascular tissues like tendons and ligaments Anti-inflammatory modulation: suppresses pro-inflammatory cytokines while preserving the early inflammatory phase needed for tissue repair, reducing chronic inflammation without blunting healing Administration: Subcutaneous injection (most common)
The first 72-week non-diabetic obesity dose is 5 mg weekly. The lowest measured human trial dose is 1 mg weekly in type 2 diabetes. Is 2.5 mg tirzepatide therapeutic
Your provider adjusts the stack based on injury severity, your response, and lab findings at intake
